DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20191677

The impact of non-steroidal anti-inflammatory drugs use in elderly cardiovascular patients: an observational study from tertiary care in South India

Sadhna Sharma, Biju Govind, Kondal Rao

Abstract


Background: Long-term use of NSAIDs, by patients having cardiovascular conditions, has shown to increase the risk of cardiovascular events and increased risk of death. Hence, the study was conducted to determine the complications related to NSAID use by the elderly patients with cardiovascular disease (CVD).

Methods: The study was a single-center prospective observational study conducted November 2017 to October 2018. Elderly patients (>60 years) suffering from various CVDs and reported NSAID intake daily for at least one month were included. A questionnaire included demographic, treatment related history and complete details of NSAIDs intake including nature, dose, indication, source etc. The same questionnaire was again filled at the end of one-year follow-up.

Results: A total of 100 participants were included in the study. The mean age was 72±8.6 years. Majority of the patients (93%) had hypertension, and 69% of the patient had previous MI.  Five NSAIDs (diclofenac, ibuprofen, mefenamic acid, naproxen, and ketorolac) were used routinely. At least one over the counter NSAID used was reported by 86%, 57% were prescribed at least one NSAIDs by their orthopaedics and physicians. At the end of 1-year follow-up, authors found that 71% had MI (2% increase), 4% developed reinfarction, 20% had severe left ventricular failure (4% increase), 7% had atrial fibrillation (1% increase), and 2% patients died and 63% patients reported raise in systolic blood pressure by 5mmHg.

Conclusions: High prevalence of concomitant NSAID use among elderly CVD patients, which might be contributing towards increase in CVS morbidity and mortality.


Keywords


Arterial hypertension, Adverse effect, Cardiovascular disease, cardiovascular risk, Elderly, Heart failure, NSAID

Full Text:

PDF

References


Bekkering GE, Bala MM, Reid K, Kellen E, Harker J, Riemsma R, et al. Epidemiology of chronic pain and its treatment in the Netherlands. Neth J Med. 2011;69(3):141-53.

Thomas MA. Pain management–the challenge. Ochs J. 2003;5(2):15-21.

Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ. 2013;346:f3195.

Balmaceda CM. Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. BMC Musculoskeletal Dis. 2014;15(1):27.

Pawlosky N. Cardiovascular risk: are all NSAIDs alike? Can Pharm J. 2013;146(2):80-3.

Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Annals Int Med. 1994;121(4):289-300.

Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2014;16(5):821-47.

Hurst SA. Declaration of Helsinki and protection for vulnerable research participants. JAMA. 2014;311(12):1252.

Chatterjee S, Dureja GP, Kadhe G, Mane A, Phansalkar AA, Sawant S, et al. Cross-sectional study for prevalence of non-steroidal anti-inflammatory drug-induced gastrointestinal, cardiac and renal complications in India: interim report. Gastroenterol Res. 2015;8(3-4):216.

Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulat. 2011;123(20):2226-35.

Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011;19(4):184-91.

Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti‐inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clinic Pharmacol Therapeut. 2009;85(2):190-7.

Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Safety of non-steroidal anti-inflammatory drugs (SOS) project consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857.

Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GY. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147(1):109-19.

Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Archives Int Med. 1995;155(5):469-73.

Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American college of rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-74.

Campanelli CM. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults: the American geriatrics society 2012 beers criteria update expert panel. J Am Geriat Soci. 2012;60(4):616.